Triplet Induction Regimen Bests Doublet for Nasopharyngeal Carcinoma Three drugs reduced risk of disease failure, but longer follow-up needed to assess OS Mar 25, 2022
Artificial Sweeteners Not So Sweet When It Comes to Cancer Risk Consumption of certain sugar alternatives linked to a 13% higher risk of developing cancer Mar 24, 2022
Intraperitoneal Carboplatin Boosts PFS in Ovarian Cancer Should the gynecologic oncology community reconsider IP therapy? Mar 22, 2022
It's Official: Minimally Invasive Hysterectomy Not Safer in Cervical Cancer Final analysis of LACC trial confirms earlier findings Mar 21, 2022
Novel Fixed-Dose Immunotherapy Combo Wins FDA Approval Nivolumab plus relatlimab doubled progression-free survival in unresectable melanoma Mar 21, 2022
Lenvatinib Packaging for Endometrial Cancer Tied to $168 Million in Overspending Presenter breaks news at SGO that drug developer commits to overhauling dose reduction program Mar 20, 2022
Selinexor Proves Mettle in Advanced or Recurrent Endometrial Cancer Benefit was greatest among patients with wild-type p53 cancer in SIENDO trial Mar 20, 2022
Novel ADC Promising in Tough-to-Treat Ovarian Cancer Ocular AEs an issue with mirvetuximab in folate receptor alpha-high platinum-resistant disease Mar 20, 2022
Add-on Pembrolizumab Tied to Good QoL in Women With Advanced Cervical Cancer PRO-based analysis of KEYNOTE-826 trial shows favorable benefit-risk ratio Mar 19, 2022
Adjuvant Chemo Disappoints in Low-Grade Serous Ovarian Cancer Study suggests no improvement in overall survival Mar 19, 2022
Mixed Message for Ultrasound in High-Risk Cutaneous Head and Neck Cancer Nodal metastasis detected more often than by clinical exam, worrisome false-positive rate Mar 18, 2022
FDA OKs PARP Inhibitor as Adjuvant Therapy in Early Breast Cancer Olaparib (Lynparza) approved for high-risk patients with germline BRCA mutations Mar 14, 2022
Fluorescence-Guided Lumpectomy Shows Promise Imaging system reduced the need for re-excision in one-fifth of patients Mar 11, 2022
More Research Needed on Use of Premium Cigars, Report Finds These cigars seem less dangerous than cigarettes -- but it's only because of how they are smoked Mar 10, 2022
Fecal Microbiome Markers Detect Pancreatic Cancer With 'High Accuracy' These markers need to be tested in a prospective cohort before clinical impact can be determined Mar 10, 2022
Robotic Hepatectomy Shows Benefits Over Laparoscopic Surgery Shorter hospital stay, similar perioperative outcomes in matched analysis Mar 10, 2022
Radioiodine for Low-Risk Thyroid Cancer: Yea or Nay? Randomized study finds no meaningful difference in events of abnormalities between groups Mar 09, 2022
Another Casualty of COVID-19: Evidence-Based Medicine Physician laments decline in research quality, critical appraisal during pandemic Mar 09, 2022
Androgen Receptor Agonist Active in Resistant ER+ Breast Cancer Also: Combination targets uncommon form of advanced HER2-mutant disease Mar 09, 2022
Is ctDNA Useful for Surveillance in Resected CRC? Small study suggests no advantage compared to imaging alone or with CEA measurement Mar 08, 2022
More Options for Precision Medicine in Metastatic Triple-Negative Breast Cancer Moving beyond chemotherapy to immunotherapy, PARP inhibitors, ADCs, combinations Mar 08, 2022
9/11 Responders More Likely to Carry Genetic Mutations Tied to Cancer Clonal hematopoiesis seen in 10% of firefighters, medical personnel on the scene after WTC attack Mar 07, 2022
Chipping Away at the Dogma of Axillary Dissection in Breast Cancer Ongoing trials could help some women avoid even less-invasive sentinel lymph node biopsy Mar 07, 2022
Clinical Picture Brightens for HER2+ Breast Cancer With Brain Metastases New therapies breach blood-brain barrier to improve response, survival Mar 07, 2022
Honing the Indications for Adjuvant CDK4/6 Inhibition in Breast Cancer Defining high risk, considering role of Ki-67, BRCA mutations Mar 05, 2022
Check Troponin in RCC Patients Before Checkpoint-VEGFR Inhibitor Combo In JAVELIN Renal 101, those with high levels had more heart events with avelumab-axitinib Mar 05, 2022
Cancer May Heighten Odds of Guillain-Barre Syndrome Link strongest with hematologic malignancies as well as prostate, breast, and respiratory cancers Mar 03, 2022
ARB-Cancer Link May Come Down to Cumulative Exposure Does a new paper resolve the conflicting safety data on the popular antihypertensives? Mar 02, 2022
Kids With IBD Need Close Monitoring as They Grow Up Meta-analysis confirms: substantially increased cancer risk in adulthood Mar 02, 2022
Novel Therapies Active in Head and Neck Cancers High response rate with oncolytic virus plus immunotherapy in cutaneous lesions Feb 28, 2022
AI Platform Near Perfect for Predicting Thyroid Malignancy High precision for T stage, extracapsular extension, BRAF mutation Feb 27, 2022
Merkel Cell Carcinoma Much More Likely to Recur vs Other Skin Cancers 5-year recurrence rate was 40% compared with 19% for melanoma Feb 23, 2022
PD-L1 Inhibitor Fails to Meet PFS Target in Advanced Penile Cancer Atezolizumab did show some activity, with a 30% overall response rate Feb 22, 2022
Enfortumab Vedotin Promising in Neovadjuvant Therapy in Advanced Bladder Cancer Early-phase study offers 36% pCR in cisplatin-ineligible patients with muscle-invasive disease Feb 19, 2022
Enzalutamide Rechallenge Yields Small PFS Boost in Metastatic Prostate Cancer Docetaxel-enzalutamide regimen may offer another option for men who progressed on AR inhibitor Feb 18, 2022
Two PARP Inhibitors Impress as First-Line Add-Ons in mCRPC In one case, rPFS benefit was seen regardless of HRR mutational status Feb 18, 2022
Ablating High-Grade Anal Lesions Thwarts Progression to Cancer Screening followed by aggressive therapy shows benefit in phase III ANCHOR study Feb 17, 2022
Darolutamide Improves OS in Metastatic Prostate Cancer The AR inhibitor plus standard therapy led to a 32% reduced risk of death versus placebo Feb 17, 2022
Early Clinical Activity With CDK4/6 Inhibitor in Pretreated Mesothelioma Disease control in 54% of patients in first clinical evaluation of abemaciclib Feb 17, 2022
Sotorasib Impresses in Advanced Pancreatic Cancer ORR of 21% in heavily pretreated patients with a KRAS G12C mutation Feb 16, 2022
